The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

A.R. Bosieva

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

A.D. Zikiryakhodzhaev

I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Russia;
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Russia;
Peoples’ Friendship University of Russia

E.K. Saribekyan

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiology Center of the Ministry of Health of Russia

N.N. Volchenko

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

E.A. Rasskazova

P.A. Herzen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Center of the Ministry of Health of the Russia

V.V. Efanov

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

The possibility of performing organ-sparing surgical treatment in patients with Stage IIB, IIIA, or IIIC breast cancer after neoadjuvant polychemotherapy

Authors:

A.R. Bosieva, A.D. Zikiryakhodzhaev, E.K. Saribekyan, N.N. Volchenko, E.A. Rasskazova, V.V. Efanov

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(6): 12‑17

Views: 668

Downloaded: 42


To cite this article:

Bosieva AR, Zikiryakhodzhaev AD, Saribekyan EK, Volchenko NN, Rasskazova EA, Efanov VV. The possibility of performing organ-sparing surgical treatment in patients with Stage IIB, IIIA, or IIIC breast cancer after neoadjuvant polychemotherapy. P.A. Herzen Journal of Oncology. 2022;11(6):12‑17. (In Russ.)
https://doi.org/10.17116/onkolog20221106112

Recommended articles:
Cost-effectiveness analysis of tala­zoparib and olaparib for breast cancer in adults. Medi­cal Technologies. Asse­ssment and Choice. 2023;(1):89-98
Quality of life in breast cancer patients after imme­diate two-stage reco­nstruction. Plastic Surgery and Aesthetic Medi­cine. 2023;(2):47-53
Comprehensive analysis of the effi­cacy of personalized reha­bilitation programs in patients with breast cancer. Voprosy kuro­rtologii, fizioterapii, i lechebnoi fizi­cheskoi kultury. 2023;(2):31-38
Cardiac moni­toring of neoadjuvant chemotherapy in a patient with breast cancer. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2023;(3):309-312

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation



We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.